Detail of "949-99-5"

CAS Number:
949-99-5
Name:
4-Nitro-3-phenyl-L-alanine
Molecular Structure:
Formula:
C₉H₁₀N₂O₄
Molecular Weight:
210.19
Synonyms:
L-Phenylalanine,4-nitro-;Alanine,3-(p-nitrophenyl)-, L- (8CI);(S)-4-Nitrophenylalanine;3-(4-Nitrophenyl)-L-alanine;4-Nitro-L-phenylalanine;L-4-Nitrophenylalanine;L-p-Nitrophenylalanine;NSC 152925;p-Nitro-L-phenylalanine;p-Nitrophenylalanine;H-Phe(4-NO2)-OH;
EINECS:
213-446-8
Density:
1.408 g/cm³
Melting Point:
236-239 °C (dec.)
Boiling Point:
414.1 °C at 760 mmHg
Flash Point:
204.2 °C
Solubility:
very soluble in water
Appearance:
white to light yellow crystal powder
Hazard Symbols:
Xn,C,F
Risk Codes:
36/37/38-22-34-11
Safety:
26-36/37/39-22-45-16 Details

Detection of the mutagenic (carcinogenic) activity of some chemical substances using Salmonella typhimurium mutants (Ames method): Detection of the mutagenic (carcinogenic) activity of some chemical substances using Salmonella typhimurium mutants (Ames method). Voiculet, N.; Sbenghe, Marilena; Barbu, Cristina (Inst. Oncol., Bucharest, Rom.). Rev. Chir., Oncol., Radiol., ORL, Oftalmol., Stomatol., Oncol., 16(1), 15-28 (Hungarian) 1977. CODEN: ONCODU. DOCUMENT TYPE: Journal CA Section: 4 (Toxicology) Of 5 precursors used in the synthesis of levofalan (Sarcolysine) [1465-26-5], only L-4-nitrophenylalanine [949-99-5] was mutagenic, as shown by the method of N. B. Ames et al. (1975). When 5 bis(chloroethylnitrosourea) derivs. [ClCH2CH2NHCON(NO)]2(CH2)n (n = 2-8) were tested, the mutagenic activity increased with the increase of n. A reverse trend was obsd. for 3 bis(cyclohexylnitrosourea) derivs. II (n = 2-4).

Pharmaceuticals containing phenylalanine derivatives: Pharmaceuticals containing phenylalanine derivatives. Toyoshima, Shigeshi; Fukushima; Seto, Yoshiko; Kumashiro, Izumi (Ajinomoto Co., Inc., Japan). Eur. Pat. Appl. EP 93551 A2 9 Nov 1983, 23 pp. DESIGNATED STATES: R: DE, FR, GB. (English). (European Patent Organization). CODEN: EPXXDW. CLASS: IC: A61K045-06; A61K037-26; C07C125-065; C07C103-46; C07C103-52. ICI: A61K037-26, A61K031-27, A61K031-195, A61K031-165.Several reagents with their cas registry numbers 75466-70-5 and 2566-22-5 are used here. APPLICATION: EP 83-302290 22 Apr 1983. PRIORITY: JP 82-73306 30 Apr 1982; JP 83-65999 14 Apr 1983. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 2, 25, 34 Phenylalanine derivs. (I, R1 = H, F, NO2, OH; R2 = substituted or unsubstituted Ph or naphthyl group, etc.; X = CO, SO2 and Y = lower alkylene, substituted or unsubstituted vinylene group, CH2O or OCH2) (0.2-500 mg) are useful for enhancement of rectal or oral absorption of drugs such as insulin. Thus, N-phenoxyacetyl-4-nitro-L-phenylalanine [88556-11-0] was prepd. by the reaction of 4-nitro-L-phenylalanine [949-99-5] with phenoxyacetyl chloride [701-99-5] in alk. soln. The LD50 of the phenylalanine derivs. was >2500. Insulin [9004-10-8] tablets were prepd. contg. N-(4-methylcinnamoyl)-L-phenylalanine [88556-18-7]. The effectiveness of the derivs. in promoting insulin absorption was demonstrated in mice. .